Verrica completes enrollment in Phase 3 COVE-2 trial of YCANTH for common warts, sees data in Q1 2027

Reuters2026/08/27 12:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Verrica completed enrollment in COVE-2, the first pivotal Phase 3 trial of YCANTH for common warts.
Topline results have not been presented; data are expected in Q1 2027.
An interim power review supported full enrollment with no added patients, keeping the study blinded.
COVE-3, the second pivotal Phase 3 trial, passed 50% enrollment; topline data remain expected in mid-2027.
The program targets a label expansion into common warts, a market with no FDA-approved prescription drug therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270800PRIMZONEFULLFEED9816814) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Verrica completes enrollment in Phase 3 COVE-2 trial of YCANTH for common warts, sees data in Q1 2027

You may also like

Crypto prices